Provectus Prepares FDA Filing to Commence Phase II Trials of Xantryl

Provectus Pharmaceuticals has begun the process to start Phase II Trials for Xantryl to treat psoriasis and later eczema.

Provectus expects to begin clinical studies for psoriasis in late 2005 and eczema in 2006. Provectus Pharmaceuticals has successfully completed preclinical and Phase I studies, in Denmark and the U.S., for the treatment of psoriasis with Xantryl.